The majority of people with mood and anxiety disorders who receive the most commonly prescribed anti-depressants -- called SSRIs -- are not helped by these medications.
A new research sheds light on why Selective Serotonin Reuptake Inhibitors or SSRIs fail to work in most patients.
SSRIs are designed to increase serotonin, a neurotransmitter in the brain that is key to maintenance of mood.
"We have shown that serotonin is too high near the serotonin brain cells, reducing firing of the serotonin nerve cells through a well-documented negative feedback mechanism in the raphe nucleus.
"The result is that the hippocampus and other critical brain structures needed for mood maintenance do not get enough serotonin," explained lead researcher Jeremy D. Coplan.
"We have hypothesised in an earlier paper that this is a plausible reason why SSRIs may not work in a majority of people, because SSRIs will tend to make the high serotonin even higher in the raphe nucleus.
"The serotonin neuron may not be able to adapt and restore its firing, inducing a presumed serotonin deficit in terminal fields, evidenced by shrinkage of the hippocampus," added Coplan, a professor of psychiatry at SUNY Downstate Medical Center, in the US.
The researchers advocate that additional studies should be performed as better understanding of the serotonin system will significantly improve future treatment options.
Coplan noted that a recent large-scale study showed only a minority of patients do well on SSRIs, and of those, many lose response in a year or two.
"There is an epidemic of inadequately treated depression and psychiatrists are not well trained to deal with this challenge," he observed.
"What they often do is change from one anti-depressant to another when there is a lack of response. Eventually the patient becomes non-compliant and the patient, rather than the treatment, is blamed for the non-efficacy," he rued.
The research was published in Frontiers in Behavioural Neuroscience.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
